Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries

BACKGROUND: As alternatives to warfarin, 2 novel oral anticoagulants (NOACs), dabigatran and rivaroxaban, were approved in 2010 and 2011 to prevent stroke and other thromboembolic events in patients with atrial fibrillation. It is unclear how patient characteristics are associated with the initiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Baik, Seo Hyon, Hernandez, Inmaculada, Zhang, Yuting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051348/
https://www.ncbi.nlm.nih.gov/pubmed/27003558
http://dx.doi.org/10.18553/jmcp.2016.22.3.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051348/
https://www.ncbi.nlm.nih.gov/pubmed/27003558
http://dx.doi.org/10.18553/jmcp.2016.22.3.281

Ejemplares similares